A PYMNTS Company

Viatris Unit Mylan Cleared from DOJ Antitrust Investigation

By  |  July 2, 2024
Department of Justice

Viatris announced on Tuesday that its subsidiary, Mylan, is no longer a subject of the U.S. DOJ antitrust investigation into alleged price fixing within the generic drug industry. This development marks a significant turn in a probe that has scrutinized Mylan and several other major pharmaceutical companies for over eight years.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The DOJ’s investigation targeted Viatris’s Mylan, along with other prominent drugmakers including Israel’s Teva Pharmaceutical Industries and India’s Sun Pharmaceutical Industries, over accusations of engaging in anticompetitive practices to fix the prices of certain generic drugs. This prolonged scrutiny has also spurred multiple states to file lawsuits against these companies for similar antitrust violations.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Viatris, established through the 2020 merger of Mylan and Pfizer’s Upjohn business, produces a range of generic and branded medications, including the well-known erectile dysfunction drug Viagra. The specific investigation concerning Mylan was centered on the pricing and marketing strategies of its generic doxycycline antibiotic, a medication used to treat various bacterial infections such as acne, pneumonia, Lyme disease, chlamydia, and syphilis. According to the U.S. Food and Drug Administration’s database, doxycycline is manufactured by over a dozen companies.

    In a statement, Viatris conveyed that the DOJ does not foresee any further actions regarding the pricing and sales practices of its generic drugs. However, the company did not provide details on the rationale behind the DOJ’s decision to drop Mylan from the probe.

    Despite this reprieve, Viatris emphasized its commitment to defending itself against the remaining civil lawsuits related to the DOJ allegations of antitrust behavior. The company continues to navigate the legal landscape as it maintains its stance against these claims.

    This latest development provides some relief for Viatris amid ongoing legal challenges but underscores the broader scrutiny facing the pharmaceutical industry over drug pricing practices. As the landscape evolves, Viatris remains vigilant in its legal defense while advancing its mission to deliver accessible healthcare solutions globally.

    Source: Reuters